The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

Forte Biosciences (FBRX) stock soared on Monday after the clinical-stage biopharmaceutical company announced results from a Phase 1b trial of FB102. This is the company’s lead program designed to ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.

Most cases of T-PLL are acquired, but some cases evolve from constitutional diseases, such as ataxia-telangiectasia, caused by the ATM gene mutation (ataxia-telangiectasia mutant). 3 In most cases, ...

ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues.